Revision History

Results from the OPTIMA trial, presented at ASCO 2026, show that a 50-gene test called Prosigna can identify 68% of breast cancer patients traditionally recommended for chemotherapy who can safely skip it with no difference in survival — findings that could spare more than 150,000 women annually in the U.S. alone. But questions about racial equity, regulatory oversight, test discordance, and long-term follow-up data complicate the path from clinical trial to universal standard of care.